Risk of Thyroid Tumors Linked to GLP-1 Receptor Agonist Use: A Past Patient Study

Duality of Interest. R.K. is an associate editor of the Journal of the American Medical Association and reported receiving support from the Doris Duke Charitable Foundation. He also receives research support through Yale from Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of U.S. Provisional Patent Applications 63/619,241; 63/606,203; 63/177,117; 63/346,610; 63/428,569; and 63/484,426 unrelated to the current work. He is also a cofounder of Evidence2Health and Ensight-AI, both representing precision health platforms to improve evidence-based cardiovascular care. S.L.D. reports receiving grants from Alnylam Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Biodesix, Inc.; Celgene Corporation; Cerner Enviza; GSK PLC; Janssen Pharmaceuticals, Inc.; Novartis International AG; and Parexel International Corporation through the University of Utah or Western Institute for Veteran Research outside the submitted work. K.K.C.M. reported receiving support through a Maplethorpe Fellowship and the National Institute of Health Research, U.K.; European Commission Framework Horizon 2020; Hong Kong Research Grant Council; and Innovation and Technology Commission of the Hong Kong Special Administration Region Government outside the submitted work. In the past 3 years, H.M.K. received expenses and/or personal fees from UnitedHealth, Element Science, Aetna, Reality Labs, Tesseract/4Catalyst, F-Prime, the Siegfried and Jensen Law Firm, Arnold and Porter Law Firm, and Martin/Baughman Law Firm. He is a cofounder of Refactor Health and HugoHealth and is associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare & Medicaid Services and through Yale University from Johnson & Johnson. No other potential conflicts of interest relevant to this article were reported.